reported that DN T cells combined with the chemotherapeutic drug Daunorubicin efficiently kill chemotherapy-resistant primary AML cells, producing synergistic effects, and these effects are induced by increased expression of NKG2D and DNAM-1 ligands on leukemia cells by Daunorubicin (99). This evidence concerns the gene CD226 and leukemia.